Sunday, 23 Feb 2020

Cipher Pharmaceuticals Comments on Supply Chain Impact from Hurricane Maria

MISSISSAUGA, ON: Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on the impact from Hurricane Maria to its manufacturing partner's facilities in Puerto Rico. Galephar Pharmaceutical Research ("Galephar") operates two manufacturing facilities in Puerto Rico.

The facility in Humacao manufactures Absorica, Epuris, and Lipofen products, and the facility in Juncos manufactures Conzip and Durela products.

Galephar has informed Cipher that the facility in Juncos sustained some minor weather-related damage that has been repaired. Galephar also informed the Company that the facility in Humacao sustained damage to the exterior of the production building; however, the production suites and equipment were unaffected. Clean-up and repair work at the Humacao facility has commenced and is ongoing. Galephar expects to have the Humacao facility operational by mid- to late-November 2017.

Based on current inventory levels with the Company's various distribution partners, recent and pending product shipments, and the current timeline for the resumption of production at the Humacao facility, Cipher does not anticipate an interruption in Absorica or Epuris supply. Further, no material impact is anticipated across Cipher's full product portfolio.

The Company continues to monitor the situation closely and will provide an update on the status of the facilities and product supply as additional information becomes available.

(PRN | 2 years ago)